Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Factors Influencing Choice of Second-Generation BTKi Monotherapy
Specialists discuss factors influencing the choices of second-generation BTK monotherapy.
EP: 1.Recent Trends and Innovations in the Management of CLL
EP: 2.CLL Treatment Landscape: Overview of BTK Inhibitors
EP: 3.Evaluating Value of BTK Inhibitors in CLL Treatment
Now Viewing
EP: 4.Factors Influencing Choice of Second-Generation BTKi Monotherapy
EP: 5.Empowering Patients: Key Considerations for BTK Inhibitor Adherence
EP: 6.Optimizing Therapy Sequencing in CLL
EP: 7.Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection
EP: 8.Decision-Making in CLL: The Role of Real-World Evidence
EP: 9.Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment
EP: 10.Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization
EP: 11.Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers
EP: 12.The Inflation Reduction Act: Implications for Patient Access in CL
EP: 13.Patient Access Advocacy for BTK Inhibitors
EP: 14.Future Directions of BTK Inhibitors in Leukemia and Lymphoma
Video content above is prompted by the following question(s):
- When considering monotherapy with second-generation BTKi, what factors do you consider when choosing between available agents?
Related Videos
Related Content
Real-World Data Support Safety, Efficacy of Venetoclax for CLL
August 29th 2025Article
A single-center study comparing patients with chronic lymphocytic leukemia receiving venetoclax as part of a clinical trial and patients receiving it in routine clinical practice showed very high complete response rates in both groups.
Read More
